Knockdown of p21-activated Kinase 6 Inhibits Prostate Cancer Growth and Enhances Chemosensitivity to Docetaxel

Urology

Volumn 73, Issue 6, 2009, Pages 1407-1411

  Wen, Xingqiao ^a   Li, Xiaojuan ^a   Liao, Bing ^a   Liu, Yong ^a   Wu, Jieying ^a   Yuan, Xiaoxu ^a   Ouyang, Bin ^a   Sun, Qipeng ^a   Gao, Xin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; MATRIGEL; P21 ACTIVATED KINASE 6; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; XENOGRAFT;

ANTINEOPLASTIC AGENTS; CELLS, CULTURED; COMBINED MODALITY THERAPY; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; P21-ACTIVATED KINASES; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 67349169227     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.09.041     Document Type: Article

References (24)

1. Yang F., Li X., Sharma M., et al. Androgen receptor specifically interacts with a novel p21-activated kinase, PAK6. J Biol Chem 276 (2001) 15345-15353
2. Lee S.R., Ramos S.M., Ko A., et al. AR and ER interaction with a p21-activated kinase (PAK6). Mol Endocrinol 16 (2002) 85-99
3. Etienne-Manneville S., and Hall A. Rho GTPases in cell biology. Nature 420 (2002) 629-635
4. Kumar R., Gururaj A.E., and Barnes C.J. p21-Activated kinases in cancer. Nat Rev Cancer 6 (2006) 459-471
5. Kumar R., and Vadlamudi R.K. Emerging functions of p21-activated kinases in human cancer cells. J Cell Physiol 193 (2002) 133-144
6. Jaffer Z.M., and Chernoff J. p21-Activated kinases: three more join the Pak. Int J Biochem Cell Biol 34 (2002) 713-717
7. Schrantz N., Correia J., Fowler B., et al. Mechanism of p21-activated kinase 6-mediated inhibition of androgen receptor signaling. J Biol Chem 279 (2004) 1922-1931
8. Montero A., Fossella F., Hortobagyi G., et al. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6 (2005) 229-239
9. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
10. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
11. Sella A., Sternberg C., Kovel S., et al. Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer. BJU Int 100 (2007) 533-535
12. Michels J., Montemurro T., Murray N., et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?. Cancer 106 (2006) 1041-1046
13. Adam L., Vadlamudi R., Kondapaka S.B., et al. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 273 (1998) 28238-28246
14. Vadlamudi R.K., Adam L., Wang R.A., et al. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem 275 (2000) 36238-36244
15. Vadlamudi R.K., Bagheri-Yarmand R., Yang Z., et al. Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cells 5 (2004) 575-585
16. Kaur R., Liu X., Gjoerup O., et al. Activation of p21 activated kinase 6 (PAK6) by MAP kinase 6 and p38 MAP kinase. J Biol Chem 280 (2005) 3323-3330
17. Nheu T.V., He H., Hirokawa Y., et al. The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Cancer J 8 (2002) 328-336
18. Bagheri-Yarmand R., Vadlamudi R.K., Wang R.A., et al. Vascular endothelial growth factor upregulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. J Biol Chem 275 (2000) 39451-39457
19. Wang T.H., Wang H.S., and Song Y.K. Paclitaxel-induced cell death, where the cell cycle and apoptosis come together. Cancer 88 (2000) 2619-2628
20. Krendel M., Zenke F.T., and Bokoch G.M. Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton. Nat Cell Biol 4 (2002) 294-301
21. Wittmann T., Bokoch G.M., and Waterman-Storer C.M. Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1. J Biol Chem 279 (2004) 6196-6203
22. Tang Y., Yu J., and Field J. Signals from the Ras, Rac, and Rho GTPases converge on the Pak protein kinase in Rat-1 fibroblasts. Mol Cell Biol 19 (1999) 1881-1891
23. Hall A. Rho GTPases and the actin cytoskeleton. Science 279 (1998) 509-514
24. Asanuma K., Yanagida-Asanuma E., Faul C., et al. Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signaling. Nat Cell Biol 8 (2006) 485-491